| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 01/15/2003 | CN1098684C Orally administerable pharmaceutical formulations |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506785 Establishing the status of the mammal as presently or prospectively being in early stages of degeneration of articular cartilage or subchondral bone in one or more joinsts, administering a xanthine chondroprotective compound |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506773 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506770 Antiviral compounds |
| 01/14/2003 | US6506748 Aromatic heterocyclic compounds as antiinflammatory agents |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506555 Use of HIV protease inhibiting compounds |
| 01/14/2003 | CA2249501C Method of preparing and using isoflavones |
| 01/14/2003 | CA2116859C Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| 01/10/2003 | CA2415709A1 Remedies for bone diseases |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002713A2 Antibodies to opgl |
| 01/09/2003 | WO2003002607A1 Reducing immunogenicities of immunoglobulins by framework-patching |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002569A1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002144A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/09/2003 | WO2003002130A1 Fat-binding polymers |
| 01/09/2003 | WO2003002124A1 USE OF BIS-ACID(5-ANDROSTEN-17-ONE-3β-HYDROXYL) DIESTERS FOR MANUFACTURE PHARMACEUTICALS |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002108A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | WO2003002105A2 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002064594A3 6-substituted pyrido-pyrimidines |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002047686A8 Substituted-4-quinolones |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008911 Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008895 Prostaglandin agonists |
| 01/09/2003 | US20030008893 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation |
| 01/09/2003 | US20030008877 CCR5 antagonists useful for treating AIDS |
| 01/09/2003 | US20030008876 Can mimic or block the effect of extracellular calcium on a cell surface calcium receptor; for use in therapy |
| 01/09/2003 | US20030008872 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008867 Compounds |
| 01/09/2003 | US20030008829 For therapy and prophylaxis of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis, psoriasis |
| 01/09/2003 | US20030008809 Use of 5-HT (3) receptor antagonists for treating musculoeskeletal diseases |
| 01/09/2003 | US20030008390 Genetically engineered cell for use in the generation of viral vector for use in gene therapy |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | CA2490219A1 Fat-binding polymers |
| 01/09/2003 | CA2452390A1 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452169A1 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | CA2452058A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | CA2451955A1 Antibodies to opgl |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451236A1 Peptides for use as translocation factors |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2450356A1 Bone anabolic compounds and methods of use |
| 01/09/2003 | CA2424645A1 New use of dipeptidyl peptidase iv inhibitors |
| 01/09/2003 | CA2418543A1 New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/08/2003 | EP1273582A1 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273303A1 Pharmaceutical composition comprising a mixture of at least two rBMPs and the use thereof in the treatment of orthopaedic and dental patients |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272666A1 A functional assay of high-density lipoprotein |
| 01/08/2003 | EP1272634A1 Human ion channel protein and polynucleotides encoding the same |
| 01/08/2003 | EP1272614A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 01/08/2003 | EP1272530A1 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/08/2003 | EP1272518A2 Cd20/ige-receptor like molecules and uses thereof |
| 01/08/2003 | EP1272515A2 Immunoregulator |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272513A2 Neurogenic compositions and methods |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |